Nondiabetic-derived Gr-1⁺CD11b⁺ cells promote injury-induced neovascularization. (A) Detection of GFP⁺ Gr-1⁺CD11b⁺ cells (arrows) 5 days after injection into wounds. (B) Representative plots from flow cytometric analysis of CD34⁺ cells (red) and CD34⁻ cells (blue) in wounds following injection of Gr-1⁺CD11b⁺ cells into wounds. (C) Quantification of flow cytometric analysis data (as in panel B) of CD34⁺ cells from digested wound tissue from each treatment group at day 7 after wounding. (Di) A representative hematoxylin and eosin staining of 5-μm sections of day 7 wounds showing area used for analysis of neovascularization (granulation tissue). Image shown is original magnification ×40. (ii-iii) Representative images of immunohistochemistry of 5-μm wound sections labeled with anti-CD34 antibody (brown), and counterstained with hematoxylin (blue). Arrows show new microvessels. Images shown are original magnification ×400 (ii) and ×1000 (iii). (E) Quantification of CD34⁺ microvessels in wound tissue sections as shown in panel D. DBDCs, diabetic-derived Gr-1⁺CD11b⁺ cells; NDBDCs, nondiabetic-derived Gr-1⁺CD11b⁺ cells; PBS, phosphate-buffered saline. Error bars represent SEM, *P ≤ .05, ***P ≤ .001.